Skip to main content

The Glucox Biotech Team

Meet the dedicated professionals at the heart of Glucox Biotech, committed to pioneering advancements in metabolic disease therapeutics and more.

Management Team

Per Wikström, Ph.D.

Ceo & Co-Founder

Dr. Per Wikström brings a transformative vision to the world of metabolic disorders, insulin resistance, and diabetes. With a legacy of leadership roles at pharmaceutical giants like Immunex, Pharmacia, and Pfizer, he has become an industry luminary. His expertise stretches from small non-peptide to protein pharmaceuticals, propelling them from conceptual stages to viable drug candidates. Guided by a philosophy that prioritizes transparent and authentic results, Dr. Wikström’s contributions stand as a testament to scientific rigor and ingenuity. At Glucox Biotech, he leads with an unwavering commitment to revolutionize patient care.

Board of Directors

Johan Viberg, M.Sc.

Chairman of the Board
Johan Viberg brings a multifaceted approach to his role as Chairman of the Board at Glucox Biotech. His extensive background spans technology and business leadership, from startups to Fortune-500 giants like Adobe Systems, as well as governmental agencies across multiple continents. In the realm of drug discovery, Johan has specialized early in his career in the development of therapeutic peptides, focusing on treatments for cancer and central nervous system disorders. His unique perspective on technology’s role in healthcare innovation is grounded in a unique understanding of molecule identification and optimization, dovetailing seamlessly with Glucox Biotech’s mission to transform patient outcomes.

Björn Sundeby

Board Member & Lead Investor
Björn Sundeby is not just a majority shareholder and board member at Glucox Biotech; he’s a serial entrepreneur with a knack for identifying high-growth opportunities. As the founder and principal shareholder of IST, a rapidly expanding EdTech company with global reach headquartered in Sweden, Björn has a proven track record for driving innovation and scaling businesses. His unique blend of entrepreneurial vision and investment acumen makes him a critical force behind Glucox Biotech’s ambition to redefine the future of healthcare.

Alan Harris, Ph.D.

Board Member

Dr. Alan Harris brings a wealth of pharmaceutical expertise to his role as a Non-Executive Director on the Glucox Biotech board. Serving as Senior Vice President of R&D at Switzerland-based Ferring Pharmaceuticals, his leadership has been instrumental in advancing groundbreaking research and product development. Dr. Harris’ cross-border experience and in-depth knowledge in pharmaceutical R&D make him an invaluable asset to Glucox Biotech, contributing a unique blend of scientific rigor and strategic insight to the company’s ambitious goals.

Advisory Board

Kyriaki (Kiki) Thermos, Ph.D.

Advisory Board Member

Kyriaki (Kiki) Thermos, Ph.D., is a distinguished Professor of Pharmacology at the University of Crete’s School of Medicine. With a foundational education in Chemistry from the University of Patras and advanced degrees from New York University, Dr. Thermos has dedicated her postdoctoral work to Neuropsychopharmacology/Neuropharmacology at the University of Pennsylvania School of Medicine.

Her research, starting at the new millennium, concentrated on unraveling the complex mechanisms behind ischemia-induced retinopathies, focusing on excitotoxicity and oxidative stress. Dr. Thermos is at the forefront of exploring the pharmacology of the endocannabinoid system, neurosteroidal neurotrophins, and NADPH Oxidase inhibitors in rodent retinas. Her work emphasizes neuroprotection, inflammation, and angiopathy, with a keen interest in the pharmacodynamic and pharmacokinetic profiles of selective agents.

Through in vivo experimental models, she investigates the therapeutic potential of these pharmacological families, particularly highlighting the neuroprotective and anti-inflammatory properties of endocannabinoid system modulators.

Dr. Antonio Bechara Ghobril

Advisory Board Member

Dr. Bechara Ghobril embodies a forward-thinking approach in the realm of ophthalmology. His career debuted in SwissVisio Montchoisi in Lausanne (under the mentorship of Professor André Mermoud) and is continuing his training in renowned institutions across Paris in the retina and ocular oncology field. He is currently in the Hôpital Intercommunal de Créteil under the mentorship Prof. Eric Soueid. He has honed a unique expertise in ophthalmic conditions, bridging the gap between intricate medical knowledge and clinical application.

His involvement in humanitarian projects not only demonstrated his commitment to making a positive impact but also significantly expanded his knowledge in the field of ophthalmology.

Leading with a philosophy that champions meticulous research and patient-focused solutions, Dr. Bechara Ghobril’s work in ophthalmology is not just a professional pursuit but a testament to his commitment to enhancing patient outcomes and expanding the boundaries of medical knowledge in eye care.

Collaborative Approach

Based in Stockholm, Glucox Biotech AB thrives on collaboration. Alongside our core team, we work closely with academic researchers and contract research organizations. Our collective efforts are geared towards developing effective therapeutics for type 2 diabetes, hyperglycemia, insulin resistance, and related complications like diabetic retinopathy (DR). Additionally, our research extends to exploring preventive measures for cellular damage in ischemic stroke and heart infarction.

“The opportunities to find effective treatments have never been greater.”

Per Wikström, CEO & Co-Founder of Glucox Biotech

Let's Shape the Future Together

Connect with Glucox Biotech to explore collaborative opportunities and discover our innovative research.